Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants

Vaccine

Volumn 19, Issue 4-5, 2000, Pages 413-422

  McCluskie, Michael J ^a   Davis, Heather L ^a,b,c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c PFIZER INC   (United States)

Author keywords

Adjuvant; CpG; Mucosal

Indexed keywords

FLUVIRAL; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; HEPATITIS B; IMMUNIZATION; IMMUNOSTIMULATION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TETANUS; TETANUS PROPHYLAXIS; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ANIMAL; BASE SEQUENCE; COMPARATIVE STUDY; CPG ISLANDS; FEMALE; HEPATITIS B SURFACE ANTIGENS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; SUPPORT, NON-U.S. GOV'T; TETANUS TOXOID; TH2 CELLS; VACCINES, COMBINED;

EID: 0034668209     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00208-5     Document Type: Article

References (39)

1. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine. 10:1992;75-88.
2. McGhee J.R., Mestecky J., Elson C.O., Kiyono H. Regulation of IgA synthesis and immune response by T cells and interleukins. J. Clin. Immunol. 9:1989;175-199.
3. Staats H.F., Montgomery S.P., Palker T.J. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res. Hum. Retroviruses. 13:1997;945-952.
4. Kozlowski P.A., Cu-Uvin S., Neutra M.R., Flanigan T.P. Mucosal vaccination strategies for women. J. Infect. Dis. 179:1999;S493-S498.
5. Eriksson K., Quiding-Järbrink M., Osek J., Moller Å., Björk S., Holmgren J., Czerkinsky C. Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination. Infect. Immun. 66:1998;5889-5896.
6. Kozlowski P.A., Cu-Uvin S., Neutra M.R., Flanigan T.P. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect. Immun. 65:1997;1387-1394.
7. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. J. Immunol. 22:1992;2277-2281.
8. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:1992;622-647.
9. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G., Klinman D. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
10. Yi A.K., Klinman D.M., Martin T.L., Matson S., Krieg A.M. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J. Immunol. 157:1996;5394-5402.
11. Klinman D., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFN-γ Proc. Natl. Acad. Sci. USA. 93:1996;2879.
12. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant Hepatitis B surface antigen. J. Immunol. 160:1998;870-876.
13. Sparwasser T., Koch E.S., Vabulas R.M., Heeg K., Lipford G.B., Ellwart J.W., Wagner H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28:1998;2045-2054.
14. Halpern M.D., Kurlander R.J., Pisetsky D.S. Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α Cell. Immunol. 167:1996;72.
15. Davis H.L., Suparto I., Weeratna R., Jumintarto, Iskandriati D., Chamzah S., Ma'ruf A., Nente C., Pawitri D., Krieg A.M., Heriyanto, Smits W., Sajuthi D. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 18:2000;1920-1924.
16. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.D., Sato Y., Ronaghy A., Kornbluth R.S., Richman D.D., Carson D.A., Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:1997;849-854.
17. Lipford G.B., Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27:1997;2340-2344.
18. Lipford G.B., Sparwasser T., Bauer M., Zimmermann S., Koch E.S., Heeg K., Wagner H. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol. 27:1997;3420-3426.
19. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1997;1623-1631.
20. Jones T.R., Obaldia N., Gramzinski R.A., Charoenvit Y., Kolodny N., Kitov S., Davis H.L., Krieg A.M., Hoffman S.L. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine. 17:1999;3065-3071.
21. McCluskie M.J., Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161:1998;4463-4466.
22. McCluskie M.J., Davis H.L. CpG DNA as mucosal adjuvant. Vaccine. 18:1999;231-237.
23. Horner A.A., Ronaghy A., Cheng P.M., Nguyen M.D., Cho H.J., Broide D., Raz E. Immunostimulatory DNA is a potent mucosal adjuvant. Cell. Immunol. 190:1998;77-82.
24. Moldoveanu Z., Love-Homan L., Huang W.Q., Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine. 16:1998;1216-1224.
25. Hirabayashi Y., Kurata H., Funato H., Nagamine T., Aizawa C., Tamura S., Shimada K., Kurata T. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine. 8:1990;243-248.
26. Rudin A., Johansson E.L., Bergquist C., Holmgren J. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect. Immun. 66:1998;3390-3396.
27. Kleanthous H., Myers G.A., Georgakopoulos K.M., Tibbitts T.J., Ingrassia J.W., Gray H.L., Ding R., Zhang Z.Z., Lei W., Nichols R., Lee C.K., Ermak T.H., Monath T.P. Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect. Immun. 66:1998;2879-2886.
28. Cheng E., Cardenas-Freytag L., Clements J.D. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine. 18:1999;38-49.
29. Gallichan W.S., Rosenthal K.L. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine. 13:1995;1589-1595.
30. Haneberg B., Kendall D., Amerongen H.M., Apter F.M., Kraehenbuhl J.P., Neutra M.R. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect. Immun. 62:1994;15-23.
31. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine. 12:1994;387-400.
32. Quiding-Järbrink M., Nordström I., Granström G., Kilander A., Jertborn M., Butcher E.C., Lazarovits A.I., Holmgren J., Czerkinsky C. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J. Clin. Invest. 99:1997;1281-1286.
33. Kantele A., Hakkinen M., Moldoveanu Z., Lu A., Savilahti E., Alvarez R.D., Michalek S., Mestecky J. Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect. Immun. 66:1998;5630-5635.
34. Eriksson K., Quiding-Järbrink M., Osek J., Nordström I., Hjulström M., Holmgren J., Czerkinsky C. Anatomic segmentation of the intestinal immune response in nonhuman primates: differential distribution of B cells after oral and rectal immunizations to sites defined by their source of vascularization. Infect. Immun. 67:1999;6210-6212.
35. Beagley K.W., Husband A.J. Intraepithelial lymphocytes: origins, distribution, and function. Crit. Rev. Immunol. 18:1998;237-254.
36. Abreu-Martin M.T., Targan S.R. Regulation of immune responses of the intestinal mucosa. Crit. Rev. Immunol. 16:1996;277-309.
37. Williams N. T cells on the mucosal frontline. Science. 280:1998;198-200.
38. Romagnani S. Th1/Th2 cells. Inflamm. Bowel. Dis. 5:1999;285-294.
39. Singh V.K., Mehrotra S., Agarwal S.S. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol. Res. 29:1999;147-161.